rg-2833
Small moleculeexperimental
RG2833 is a compound originally developed by the Scripps Insitute for the treatment of Friedrick's Ataxia. RG2833 is a potent and selective inhibitor of neuronal histone deacetylase. RG2833 has been granted orphan drug status has been investigated in phase one clinical trials. There has also been proof of concept studies conducted for the treatment of Parkinson's disease. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Indications
Studied for
Chemistry & pharmacology
Loading structure…
SMILES
CC1=CC=C(C=C1)C(=O)NCCCCCC(=O)NC2=CC=CC=C2N- Mol. weight
- 339.4314 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS17V14R89EU ↗